BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17049330)

  • 1. ED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation.
    Okuda N; Takeda S; Shinomiya K; Muneta T; Itoh S; Noda M; Asou Y
    Bone; 2007 Feb; 40(2):281-92. PubMed ID: 17049330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone.
    Harada S; Mizoguchi T; Kobayashi Y; Nakamichi Y; Takeda S; Sakai S; Takahashi F; Saito H; Yasuda H; Udagawa N; Suda T; Takahashi N
    J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells.
    Ishizuka S; Kurihara N; Miura D; Takenouchi K; Cornish J; Cundy T; Reddy SV; Roodman GD
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):331-4. PubMed ID: 15225795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
    Saito H; Takeda S; Amizuka N
    J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts.
    Inada M; Tsukamoto K; Hirata M; Takita M; Nagasawa K; Miyaura C
    Biochem Biophys Res Commun; 2008 Aug; 372(3):434-9. PubMed ID: 18489902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1 Alpha-hydroxyvitamin D2 and 1 alpha-hydroxyvitamin D3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats.
    Weber K; Kaschig C; Erben RG
    Bone; 2004 Sep; 35(3):704-10. PubMed ID: 15336607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 1,25-dihydroxyvitamin D3 on bone resorption and natural immunity in osteopetrotic (ia) rats.
    Schneider GB; Relfson M; Langman CB
    J Bone Miner Res; 1994 Apr; 9(4):585-91. PubMed ID: 8030447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease.
    Ishizuka S; Kurihara N; Reddy SV; Cornish J; Cundy T; Roodman GD
    Endocrinology; 2005 Apr; 146(4):2023-30. PubMed ID: 15618361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methyl substitution of the 25-hydroxy group on 2-methylene-19-nor-1alpha,25-dihydroxyvitamin D3 (2MD) reduces potency but allows bone selectivity.
    Grzywacz P; Plum LA; Sicinski RR; Clagett-Dame M; DeLuca HF
    Arch Biochem Biophys; 2007 Apr; 460(2):274-84. PubMed ID: 17094936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development.
    Xue Y; Karaplis AC; Hendy GN; Goltzman D; Miao D
    Hum Mol Genet; 2005 Jun; 14(11):1515-28. PubMed ID: 15843402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow ablation demonstrates that excess endogenous parathyroid hormone plays distinct roles in trabecular and cortical bone.
    Yan J; Sun W; Zhang J; Goltzman D; Miao D
    Am J Pathol; 2012 Jul; 181(1):234-44. PubMed ID: 22640808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose glucocorticoid hampers bone formation and resorption after bone marrow ablation in rat.
    Kondo N; Tokunaga K; Ito T; Arai K; Amizuka N; Minqi L; Kitahara H; Ito M; Naito M; Shu-Ying J; Oda K; Murai T; Takano R; Ogose A; Endo N
    Microsc Res Tech; 2006 Oct; 69(10):839-46. PubMed ID: 16972225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
    Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients.
    Kubodera N; Tsuji N; Uchiyama Y; Endo K
    J Cell Biochem; 2003 Feb; 88(2):286-9. PubMed ID: 12520528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A; Rogers MJ; Idris AI; Crockett JC
    Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin.
    Yang Q; McHugh KP; Patntirapong S; Gu X; Wunderlich L; Hauschka PV
    Matrix Biol; 2008 Sep; 27(7):589-99. PubMed ID: 18640270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
    Bonnelye E; Chabadel A; Saltel F; Jurdic P
    Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VDR in Osteoblast-Lineage Cells Primarily Mediates Vitamin D Treatment-Induced Increase in Bone Mass by Suppressing Bone Resorption.
    Nakamichi Y; Udagawa N; Horibe K; Mizoguchi T; Yamamoto Y; Nakamura T; Hosoya A; Kato S; Suda T; Takahashi N
    J Bone Miner Res; 2017 Jun; 32(6):1297-1308. PubMed ID: 28177161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
    Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.